| The 2022 outbreak and the pathobiology of the monkeypox virus N Kumar, A Acharya, HE Gendelman, SN Byrareddy Journal of autoimmunity 131, 102855, 2022 | 402 | 2022 |
| Impact of social determinants of health on the emerging COVID-19 pandemic in the United States S Singu, A Acharya, K Challagundla, SN Byrareddy Frontiers in public health 8, 564623, 2020 | 380 | 2020 |
| Mental health issues during and after COVID-19 vaccine era K Pandey, M Thurman, SD Johnson, A Acharya, M Johnston, EA Klug, ... Brain research bulletin 176, 161-173, 2021 | 103 | 2021 |
| SARS-CoV-2 infection leads to neurological dysfunction A Acharya, BD Kevadiya, HE Gendelman, SN Byrareddy Journal of Neuroimmune Pharmacology 15, 167-173, 2020 | 97 | 2020 |
| Animal models for SARS‐CoV‐2 research: a comprehensive literature review K Pandey, A Acharya, M Mohan, CL Ng, SP Reid, SN Byrareddy Transboundary and emerging diseases 68 (4), 1868-1885, 2021 | 78 | 2021 |
| Metagenomic study of single-nucleotide polymorphism within candidate genes associated with type 2 diabetes in an Indian population PN Mukhopadhyaya, A Acharya, Y Chavan, SS Purohit, A Mutha Genet Mol Res 9 (4), 2060-8, 2010 | 63 | 2010 |
| Immuno-epidemiology and pathophysiology of coronavirus disease 2019 (COVID-19) OA Olwenyi, SR Dyavar, A Acharya, AT Podany, CV Fletcher, CL Ng, ... Journal of Molecular Medicine 98, 1369-1383, 2020 | 49 | 2020 |
| Defining the innate immune responses for SARS-CoV-2-human macrophage interactions MM Abdelmoaty, P Yeapuri, J Machhi, KE Olson, F Shahjin, V Kumar, ... Frontiers in immunology 12, 741502, 2021 | 42 | 2021 |
| Discovery and evaluation of entry inhibitors for SARS-CoV-2 and its emerging variants A Acharya, K Pandey, M Thurman, E Klug, J Trivedi, K Sharma, CL Lorson, ... Journal of virology 95 (24), 10.1128/jvi. 01437-21, 2021 | 33 | 2021 |
| Binding of the SARS-CoV-2 envelope E protein to human BRD4 is essential for infection KR Vann, A Acharya, SM Jang, C Lachance, M Zandian, TA Holt, ... Structure 30 (9), 1224-1232. e5, 2022 | 23 | 2022 |
| Human immunodeficiency virus and severe acute respiratory syndrome coronavirus 2 coinfection: a systematic review of the literature and challenges RH Patel, A Acharya, HS Chand, M Mohan, SN Byrareddy AIDS research and human retroviruses 37 (4), 266-282, 2021 | 21 | 2021 |
| Molecular aspects of COVID-19 differential pathogenesis HA Rothan, A Acharya, SP Reid, M Kumar, SN Byrareddy Pathogens 9 (7), 538, 2020 | 21 | 2020 |
| Recent advances in the development of integrase inhibitors for HIV treatment J Trivedi, D Mahajan, RJ Jaffe, A Acharya, D Mitra, SN Byrareddy Current HIV/AIDS Reports 17, 63-75, 2020 | 21 | 2020 |
| Aerobic reduction of perchlorate by bacteria isolated in Kerala, South India A Shete, PN Mukhopadhyaya, A Acharya, BA Aich, S Joshi, VS Ghole Journal of applied genetics 49, 425-431, 2008 | 18 | 2008 |
| Biomarkers of activation and inflammation to track disparity in chronological and physiological age of people living with HIV on combination antiretroviral therapy M Thurman, S Johnson, A Acharya, S Pallikkuth, M Mahesh, ... Frontiers in immunology 11, 583934, 2020 | 17 | 2020 |
| PI3K‐α/mTOR/BRD4 inhibitor alone or in combination with other anti‐virals blocks replication of SARS‐CoV‐2 and its variants of concern including Delta and Omicron A Acharya, AS Pathania, K Pandey, M Thurman, KR Vann, ... Clinical and Translational Medicine 12 (4), 2022 | 16 | 2022 |
| Therapeutic implications of SARS-CoV-2 dysregulation of the gut-brain-lung axis SD Johnson, OA Olwenyi, N Bhyravbhatla, M Thurman, K Pandey, ... World Journal of Gastroenterology 27 (29), 4763, 2021 | 16 | 2021 |
| COVID‐19 and AIDS: Outcomes from the coexistence of two global pandemics and the importance of chronic antiretroviral therapy RH Patel, A Acharya, M Mohan, SN Byrareddy Journal of medical virology 93 (2), 641, 2021 | 15 | 2021 |
| A study on genital tuberculosis and infertility in Indian population SS Nadgouda, PN Mukhopadhyaya, A Acharya, A Nagee, PD Kunjadia Archives of Medicine 2 (1), 2010 | 15 | 2010 |
| Blockade of SARS-CoV-2 infection in vitro by highly potent PI3K-α/mTOR/BRD4 inhibitor A Acharya, K Pandey, M Thurman, KB Challagundala, KR Vann, ... Biorxiv, 2021.03. 02.433604, 2021 | 14 | 2021 |
Siddappa N. ByrareddyUniversity of Nebraska Medical Center在 unmc.edu 的电子邮件经过验证
